- Home
- SAVA vs CGEN Comparison
SAVA vs CGEN Comparison
Compare SAVA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- CGEN
- Stock Information
- Founded
- SAVA 1998
- CGEN 1993
- Country
- SAVA United States
- CGEN Israel
- Employees
- SAVA N/A
- CGEN N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAVA Health Care
- CGEN Health Care
- Exchange
- SAVA Nasdaq
- CGEN Nasdaq
- Market Cap
- SAVA 134.2M
- CGEN 142.8M
- IPO Year
- SAVA N/A
- CGEN 2000
- Fundamental
- Price
- SAVA $2.56
- CGEN $1.60
- Analyst Decision
- SAVA Buy
- CGEN Strong Buy
- Analyst Count
- SAVA 3
- CGEN 2
- Target Price
- SAVA $111.50
- CGEN $4.00
- AVG Volume (30 Days)
- SAVA 12.4M
- CGEN 445.1K
- Earning Date
- SAVA 11-07-2024
- CGEN 11-12-2024
- Dividend Yield
- SAVA N/A
- CGEN N/A
- EPS Growth
- SAVA N/A
- CGEN N/A
- EPS
- SAVA N/A
- CGEN 0.02
- Revenue
- SAVA N/A
- CGEN $59,852,000.00
- Revenue This Year
- SAVA N/A
- CGEN $57.27
- Revenue Next Year
- SAVA N/A
- CGEN N/A
- P/E Ratio
- SAVA N/A
- CGEN $88.75
- Revenue Growth
- SAVA N/A
- CGEN 698.03
- 52 Week Low
- SAVA $2.55
- CGEN $1.35
- 52 Week High
- SAVA $42.20
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- SAVA 22.85
- CGEN 51.01
- Support Level
- SAVA $2.78
- CGEN $1.55
- Resistance Level
- SAVA $3.28
- CGEN $1.68
- Average True Range (ATR)
- SAVA 0.26
- CGEN 0.08
- MACD
- SAVA 0.25
- CGEN 0.01
- Stochastic Oscillator
- SAVA 0.00
- CGEN 52.17
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.